PHARMACOKINETIC DRUG
INTERACTIONS
Presented by
Syed Imran
Guided by
Prof. Mrs. Vidya. P. Sable
Department of Pharmaceutics
DBCOP
Besa, Nagpur
Contents
• Introduction
• Classification
• Absorption interactions
• Distribution interactions
• Metabolism interactions
• Elimination interactions
• References
INTRODUCTION
• A Drug interaction is an interaction between a drug and some
other substance, such as another drug or a certain type of food,
which leads to interaction that could manifest as an increase or
decrease in the effectiveness or an adverse reaction or a totally
new side effect that is not seen with either drug alone that can be
severe enough to alter the clinical outcome. Drug interactions are
thus:
• Mostly undesirable
• Rarely desirable(beneficial)
• Eg: Enhancement of activity of Penicillines when administered
with Probenecid.
• The drug whose activity is effected by such an interaction is called
as a “Object drug”.
• The agent which precipitates such an interaction is referred to as
the “Precipitant”.
• PHARMACOKINETIC DRUG INTERACTIONS: Altered
concentration, pharmacokinetic drug interactions occur when one
drug changes the systemic concentration of another drug, altering
‘how much’ and for ‘how long’ it is present at the site of action.
• PHARMACODYNAMIC DRUG INTERACTIONS: Altered
effect, pharmacodynamic drug interactions occur when interacting
drugs have either additive effects, in which case the overall effect
is increased, or opposing effects, in which case the overall effect is
decreased or even ‘cancelled out’.
PHARMACOKINETIC DRUG INTERACTIONS
• Pharmacokinetics is ‘what the body does to the drug’.These
interactions occur when one drug alters the concentration of
another drug (the object) with clinical consequences.
• Pharmacokinetic interactions occur when the absorption,
distribution, metabolism or elimination process of the object drug
is altered by the precipitant drug and hence such interactions are
also called as ADME interactions.
• The resultant effect is altered plasma concentration of the object
drug.
CLASSIFICATION OF PHARMACOKINETIC
DRUG INTERACTIONS
• Absorption interactions
• Distribution interactions
• Metabolism interactions
• Excretion interactions
• Absorption interactions are those where the absorption
of the object drug is altered.
• Since the oral route is the one, most frequently used to
administer drugs, interactions influencing absorption
are more likely to occur within the gastrointestinal
tract.
• The net effect of such an interaction is:
• Faster or slower drug absorption.
• More or, less drug absorption.
DRUG ABSORPTION INTERACTIONS
• Most clinically significant interactions occur due to the
following factors:
a) Changes in gastrointestinal pH
b) Changes induced by chelation
c) Changes in gastrointestinal motility
CHANGES IN GASTROINTESTINAL pH
• Absorption in the gut is governed by the gut pH, lipid
solubility and pka of the drug.
• While changes in gastric pH induced by H2 and proton
pump blockers and antacids containing Al/Mg
formulations have been shown to significantly reduce
drug bioavailability.
• However the alteration in pH has certain clinical
implications as it can result in a significant reduction in
the absorption of Ketoconazole and Itroconazole which
are insoluble in water and are only ionized at low pH,
hence gastric acidity plays an important part in this
interaction.
CHANGES INDUCED BY CHELATION
• The various possible drug interactions that occur due to
alterations in drug absorption the most clinically
significant interactions occur due to chelation or
formation of insoluble complexes.
• Clinically important interactions relate to use of
Tetracyclines as well as ciprofloxacin that can form
insoluble chelates with Ca, Al, and iron, resulting in its
reduced antibacterial effects.
• This interaction can however be avoided if the interval
between the medications is at least 2-3 hours.
• Chelation also seems to play an important part in
reducing the bioavailability of Penicillamine caused by
some antacids.
CHANGES IN GASTROINTESTINAL
MOTILITY
• Drugs that alter the stomach-emptying rate can affect the
rate of absorption of drugs as most of them are absorbed in
the small intestine.
• Drugs with anticholinergic properties like Propantheline or
those altering bowel motility like Diphenoxylate may affect
the absorption of other drugs.
• Eg: Propantheline increases the absorption of slow
dissolving Digoxin by 30% as the reduced gut motility
allows a slow dissolving Digoxin formulation more time to
pass into solution making a greater amount available for
absorption but this effect is not seen with fast dissolving
tablets.
• Metoclopramide on the other hand produces the opposite
effects on motility and digoxin absorption.
DRUG DISTRIBUTION INTERACTIONS
• Drug distribution interactions are those where the
distribution pattern of the object drug is altered.
• The major mechanism for distribution interaction is
alteration in protein-drug binding.
• Many drugs interact by displacement of each others binding
to plasma proteins.
• Acidic drugs are known to have an affinity to bind to plasma
proteins, hence when two or more are given concomitantly,
competitive binding for the same site or receptor may
displace one drug from the protein binding site increasing
the amount of the displaced free drug in plasma and various
tissues setting up an interaction leading to an enhanced
potential for toxicity.
• Eg: Concomitant administration of warfarin with
Phenylbutazone or other highly protein bound drugs leads to
increased levels of warfarin.
• The drugs most likely to lead to clinically significant
interactions are those that are: 90% or more protein bound,
those bound to tissues or having a small volume of
distribution, having a low therapeutic index, low hepatic
extraction ratios, or those that are administered I.V.
• Drugs that are more likely to displace other drugs from
protein binding sites include NSAID’s, Phenylbutazone,
salicylic acid, and sulfonamides.
METABOLISM INTERACTIONS
 Stimulation of metabolism
• Certain drugs stimulate the activity of hepatic microsomal
enzymes. This effect is referred as enzyme induction.
• The increased activity is due to enhanced enzyme synthesis
results in increased amounts of drug metabolizing enzyme.
• Enzyme induction will result in increased metabolism and
excretion and reduced effect of agent which is metabolised
by the hepatic enzymes.
• Eg : Warfarin and phenobarbital
• Phenobarbital increases the rate of metabolism of warfarin
resulting in decrease anticoagulant activity.
 Inhibition of metabolism
• If one drug inhibits metabolism of another drug it
result in prolonged action or intensified activity.
• Alcohol-disulfiram inhibit the activity of alcohol
dehydrogenase, thus inhibiting oxidation of
acetaldehyde , an oxidation product of alcohol. This
result in accumulation of acetaldehyde and
development of the characteristic unpleasant effect of
disulfiram.
DRUG ELIMINATION REACTIONS
• Drug elimination reactions are those where the excretion
pattern of the object drug is altered.
• The major routes for elimination of drugs remain the kidney
and bile, but there are no significant drug - drug interactions
through bile elimination, but only drug-disease ones.
• Some drugs are excreted from the body unchanged in the
active form, usually in the urine or via the biliary tract in the
faeces.
• Drugs that are chiefly excreted by the kidneys can get
involved in drug interactions by different mechanisms such
as competition at active transport sites, or alterations in
glomerular Filtration, passive renal tubular reabsorption or
active secretion and urinary pH.
• Changes in renal drug clearance may occur due to
effects on renal tubular function or urine pH.
• For example, probenecid reduces the renal clearance of
anionic drugs such as methotrexate and penicillin.
• Major mechanisms of excretion interactions are:
 Alteration in renal blood flow
 Alteration of urine pH
 Competition for active secretions
 Forced diuresis
• Alteration in renal blood flow- eg: NSAIDs (reduce renal blood
flow) with Lithium.
• Alteration of urine pH- eg: Antacids with Amphetamine
• Competition for active secretion- eg: Probenecid and Penicillin
References
1. D.M. Barahmankar, S. B. Jaiswal “Biopharmaceutics
and Pharmacokinetics- A Treatise” Vallabh Prakashan,
Second edition, P.no:224-233.
2. Pratibha Nand, R. K. Khar “Hospital and Clinical
Pharmacy” Birla Publication,Thirteenth edition,
P.no:270-280.
 pharmacokinetic drug interactions

pharmacokinetic drug interactions

  • 1.
    PHARMACOKINETIC DRUG INTERACTIONS Presented by SyedImran Guided by Prof. Mrs. Vidya. P. Sable Department of Pharmaceutics DBCOP Besa, Nagpur
  • 2.
    Contents • Introduction • Classification •Absorption interactions • Distribution interactions • Metabolism interactions • Elimination interactions • References
  • 3.
    INTRODUCTION • A Druginteraction is an interaction between a drug and some other substance, such as another drug or a certain type of food, which leads to interaction that could manifest as an increase or decrease in the effectiveness or an adverse reaction or a totally new side effect that is not seen with either drug alone that can be severe enough to alter the clinical outcome. Drug interactions are thus: • Mostly undesirable • Rarely desirable(beneficial) • Eg: Enhancement of activity of Penicillines when administered with Probenecid. • The drug whose activity is effected by such an interaction is called as a “Object drug”. • The agent which precipitates such an interaction is referred to as the “Precipitant”.
  • 4.
    • PHARMACOKINETIC DRUGINTERACTIONS: Altered concentration, pharmacokinetic drug interactions occur when one drug changes the systemic concentration of another drug, altering ‘how much’ and for ‘how long’ it is present at the site of action. • PHARMACODYNAMIC DRUG INTERACTIONS: Altered effect, pharmacodynamic drug interactions occur when interacting drugs have either additive effects, in which case the overall effect is increased, or opposing effects, in which case the overall effect is decreased or even ‘cancelled out’.
  • 5.
    PHARMACOKINETIC DRUG INTERACTIONS •Pharmacokinetics is ‘what the body does to the drug’.These interactions occur when one drug alters the concentration of another drug (the object) with clinical consequences. • Pharmacokinetic interactions occur when the absorption, distribution, metabolism or elimination process of the object drug is altered by the precipitant drug and hence such interactions are also called as ADME interactions. • The resultant effect is altered plasma concentration of the object drug.
  • 6.
    CLASSIFICATION OF PHARMACOKINETIC DRUGINTERACTIONS • Absorption interactions • Distribution interactions • Metabolism interactions • Excretion interactions
  • 7.
    • Absorption interactionsare those where the absorption of the object drug is altered. • Since the oral route is the one, most frequently used to administer drugs, interactions influencing absorption are more likely to occur within the gastrointestinal tract. • The net effect of such an interaction is: • Faster or slower drug absorption. • More or, less drug absorption. DRUG ABSORPTION INTERACTIONS
  • 8.
    • Most clinicallysignificant interactions occur due to the following factors: a) Changes in gastrointestinal pH b) Changes induced by chelation c) Changes in gastrointestinal motility
  • 9.
    CHANGES IN GASTROINTESTINALpH • Absorption in the gut is governed by the gut pH, lipid solubility and pka of the drug. • While changes in gastric pH induced by H2 and proton pump blockers and antacids containing Al/Mg formulations have been shown to significantly reduce drug bioavailability. • However the alteration in pH has certain clinical implications as it can result in a significant reduction in the absorption of Ketoconazole and Itroconazole which are insoluble in water and are only ionized at low pH, hence gastric acidity plays an important part in this interaction.
  • 10.
    CHANGES INDUCED BYCHELATION • The various possible drug interactions that occur due to alterations in drug absorption the most clinically significant interactions occur due to chelation or formation of insoluble complexes. • Clinically important interactions relate to use of Tetracyclines as well as ciprofloxacin that can form insoluble chelates with Ca, Al, and iron, resulting in its reduced antibacterial effects. • This interaction can however be avoided if the interval between the medications is at least 2-3 hours. • Chelation also seems to play an important part in reducing the bioavailability of Penicillamine caused by some antacids.
  • 11.
    CHANGES IN GASTROINTESTINAL MOTILITY •Drugs that alter the stomach-emptying rate can affect the rate of absorption of drugs as most of them are absorbed in the small intestine. • Drugs with anticholinergic properties like Propantheline or those altering bowel motility like Diphenoxylate may affect the absorption of other drugs. • Eg: Propantheline increases the absorption of slow dissolving Digoxin by 30% as the reduced gut motility allows a slow dissolving Digoxin formulation more time to pass into solution making a greater amount available for absorption but this effect is not seen with fast dissolving tablets. • Metoclopramide on the other hand produces the opposite effects on motility and digoxin absorption.
  • 12.
    DRUG DISTRIBUTION INTERACTIONS •Drug distribution interactions are those where the distribution pattern of the object drug is altered. • The major mechanism for distribution interaction is alteration in protein-drug binding. • Many drugs interact by displacement of each others binding to plasma proteins. • Acidic drugs are known to have an affinity to bind to plasma proteins, hence when two or more are given concomitantly, competitive binding for the same site or receptor may displace one drug from the protein binding site increasing the amount of the displaced free drug in plasma and various tissues setting up an interaction leading to an enhanced potential for toxicity.
  • 13.
    • Eg: Concomitantadministration of warfarin with Phenylbutazone or other highly protein bound drugs leads to increased levels of warfarin. • The drugs most likely to lead to clinically significant interactions are those that are: 90% or more protein bound, those bound to tissues or having a small volume of distribution, having a low therapeutic index, low hepatic extraction ratios, or those that are administered I.V. • Drugs that are more likely to displace other drugs from protein binding sites include NSAID’s, Phenylbutazone, salicylic acid, and sulfonamides.
  • 14.
    METABOLISM INTERACTIONS  Stimulationof metabolism • Certain drugs stimulate the activity of hepatic microsomal enzymes. This effect is referred as enzyme induction. • The increased activity is due to enhanced enzyme synthesis results in increased amounts of drug metabolizing enzyme. • Enzyme induction will result in increased metabolism and excretion and reduced effect of agent which is metabolised by the hepatic enzymes. • Eg : Warfarin and phenobarbital • Phenobarbital increases the rate of metabolism of warfarin resulting in decrease anticoagulant activity.
  • 15.
     Inhibition ofmetabolism • If one drug inhibits metabolism of another drug it result in prolonged action or intensified activity. • Alcohol-disulfiram inhibit the activity of alcohol dehydrogenase, thus inhibiting oxidation of acetaldehyde , an oxidation product of alcohol. This result in accumulation of acetaldehyde and development of the characteristic unpleasant effect of disulfiram.
  • 16.
    DRUG ELIMINATION REACTIONS •Drug elimination reactions are those where the excretion pattern of the object drug is altered. • The major routes for elimination of drugs remain the kidney and bile, but there are no significant drug - drug interactions through bile elimination, but only drug-disease ones. • Some drugs are excreted from the body unchanged in the active form, usually in the urine or via the biliary tract in the faeces. • Drugs that are chiefly excreted by the kidneys can get involved in drug interactions by different mechanisms such as competition at active transport sites, or alterations in glomerular Filtration, passive renal tubular reabsorption or active secretion and urinary pH.
  • 17.
    • Changes inrenal drug clearance may occur due to effects on renal tubular function or urine pH. • For example, probenecid reduces the renal clearance of anionic drugs such as methotrexate and penicillin. • Major mechanisms of excretion interactions are:  Alteration in renal blood flow  Alteration of urine pH  Competition for active secretions  Forced diuresis
  • 18.
    • Alteration inrenal blood flow- eg: NSAIDs (reduce renal blood flow) with Lithium. • Alteration of urine pH- eg: Antacids with Amphetamine • Competition for active secretion- eg: Probenecid and Penicillin
  • 19.
    References 1. D.M. Barahmankar,S. B. Jaiswal “Biopharmaceutics and Pharmacokinetics- A Treatise” Vallabh Prakashan, Second edition, P.no:224-233. 2. Pratibha Nand, R. K. Khar “Hospital and Clinical Pharmacy” Birla Publication,Thirteenth edition, P.no:270-280.